May 2022: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
Migraine
FDA to Review Intranasal Zavegepant for Migraine Treatment
The NDA submission includes data from 2 pivotal studies that evaluated zavegepant in adults with at least a 1-year history of migraine and migraine attacks.
FDA Delays Decision on Meloxicam/Rizatriptan Combo for Migraine
AXS-07 is an oral agent that consists of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory drug, and rizatriptan, a 5-HT1B/1D agonist.
Labeling for Migraine Treatment Rimegepant Updated With Lactation Data
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.
Atogepant Reduces Monthly Migraine Days in Chronic Migraine Trial
The PROGRESS study compared the efficacy and safety of atogepant to placebo in 778 adults with at least a 1-year history of chronic migraine.
Elyxyb Now Available for Acute Migraine Treatment
Elyxyb is a ready-to-use oral solution formulation of celecoxib.
Erenumab vs Topiramate in Patients With Migraine: Head-to-Head Study Results
The HER-MES trial included 777 adults with episodic or chronic migraine (at least 4 migraine days/month) who were treatment-naïve, not suitable for, or had previously failed up to 3 prophylactic migraine treatments.
Eprontia Oral Solution Approved for Partial-Onset, Primary Generalized Tonic-Clonic Seizures
Eprontia is approved for the treatment of partial-onset or primary generalized tonic-clonic seizures and migraine prevention.
Newer Pharmacotherapies Compared With Triptans for Migraine Treatment
The analysis included 64 randomized clinical trials with a total of 46,442 patients.
Qulipta Approved for Preventive Treatment of Episodic Migraine
Results from ADVANCE showed statistically significantly greater decreases in mean monthly migraine days with atogepant compared with placebo.
